CLAIMS

1. A DNA according to any one of the following (a) to (d):

(a) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 2 or 4,

(b) a DNA comprising the coding region of the nucleotide sequence of SEQ ID NO: 1 or 3,

(c) a DNA encoding a protein comprising an amino acid sequence in which one or more amino acids in the amino acid sequence of SEQ ID NO: 2 or 4 have been replaced, deleted, inserted, and/or added,

(d) a DNA capable of hybridizing with a DNA comprising the nucleotide sequence of SEQ ID NO: 1 or 3 under stringent conditions.

2. The DNA of claim 1 encoding a protein capable of binding to a protein selected from the group consisting of SHP-1 protein, SHP-2 protein, SHIP protein, DAP10 protein, DAP12 protein, and FcRγ protein.

3. A protein encoded by the DNA of claim 1.

4. A vector into which the DNA of claim 1 has been inserted.

5. A host cell carrying the DNA of claim 1, or the vector of claim 4.

6. A method for producing the protein of claim 3, which comprises the steps of culturing the host cell of claim 5, and recovering an expressed protein from said host cell or the culture supernatant thereof.

7. An antibody that binds to the protein of claim 3.

8. A polynucleotide comprising at least 15 nucleotides that is complementary to a DNA comprising the nucleotide sequence of SEQ ID NO: 1 or 3, or the complementary strand thereof.

9. A method of screening for a compound that binds to the protein of claim 3, which comprises the following steps of:

(a) contacting said protein with a test sample,

(b) detecting the binding activity between said protein and said test sample, and

(c) selecting a compound capable of binding to said protein.

10. A method of screening for a compound capable of inhibiting the binding between the protein of claim 3 and a protein selected from the group consisting of SHP-1 protein, SHP-2 protein, SHIP protein, DAP10 protein, DAP12 protein, and FcRγ protein, which comprises the following steps of:

(a) contacting the protein of claim 3 with a protein selected from said group in the presence of a test sample,

(b) detecting the binding activity between said proteins, and

(c) selecting a compound capable of reducing the binding activity between said proteins compared to that detected in the absence of said test sample.

11. A method for producing an anti-allergy drug, which comprises the step of mixing the antibody of claim 7, or a compound obtained using the method of claim 9 or 10, with a pharmacologically acceptable carrier or vehicle.